BEL 20, BE0389555039

BEL 20 drops 1.87% as Brussels session ends

Published on 11/17/2026 at 18:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
The BEL 20 fell 1.87% as the Brussels session ended on Tuesday. Healthcare, financial and technology stocks led the decline, while D'Ieteren outperformed and UCB was the weakest major constituent.

Broad losses weigh on Brussels

  • The BEL 20 fell 1.87% at Tuesday's close in Brussels.
  • Healthcare, financial and technology stocks led the decline.
  • D'Ieteren was the strongest performer, while UCB, Elia and argenx posted the steepest losses.
BEL 20, BE0389555039, Illustration mit AI erstellt.

The BEL 20 fell 1.87% at the close of Tuesday's Brussels session, with losses concentrated in healthcare, financials and technology. The market summary was published by Investing.com in a Reuters-sourced report dated November 17, 2026.

Healthcare and financials lead losses

Declining stocks outnumbered advancing shares on the Brussels Stock Exchange by 72 to 22, while 13 stocks finished unchanged. The breadth of the move points to broad participation in the index's decline rather than weakness confined to a single constituent.

D'Ieteren outperforms as UCB retreats

D'Ieteren gained 0.17% to close at 174.90, making it the best performer among the constituents highlighted in the market summary. Solvay finished unchanged at 24.80, while Sofina slipped 0.75% to 265.60.

UCB was the weakest of the named constituents, falling 2.81% to 286.80. Elia declined 2.67% to 131.00 and argenx lost 2.64% to 854.40.

More coverage is available on the BEL 20 topic page.

Disclaimer...
en | BE0389555039 | BEL 20 | boerse | 70528264 | bgmi